Danazol

Chemical nature and receptor profile

Danazol is a synthetic drug with a pronounced steroid structure. Chemically, this substance is a derivative of 17α-ethynyltestosterone. Despite its structural relationship to male sex hormones, the drug's pharmacodynamic profile is unique. In the human body, it acts as a partial progestogen receptor agonist.

It is important to emphasize that the molecule does not exhibit absolute selectivity: in addition to acting on progestogen targets, it also demonstrates a certain affinity for androgen and glucocorticoid receptors, which largely determines the complex nature of its effect on the patient's endocrine system.

Mechanism of action: central blockade

The key pharmacological feature of danazol is a clear separation of its central and peripheral effects. In the periphery, the drug's own progestogen activity is assessed as extremely low. Because of this, significant direct peripheral effects in target organs (such as the uterus or mammary glands) are practically absent.

The primary site of action of the drug is in the central nervous system. The molecule has the ability to easily and rapidly cross the blood-brain barrier (BBB). Once in the brain tissue, the substance actively stimulates progestogen receptors localized in the hypothalamus and pituitary gland.

This stimulation triggers a cascade of neuroendocrine reactions via negative feedback:

1. There is a potent suppression of the secretion (release) of hypothalamic gonadotropin-releasing hormone.
2. Following this, the production of key gonadotropins of the anterior pituitary—follicle-stimulating hormone (FSH) and luteinizing hormone (LH)—is suppressed accordingly.
3. The result of such central inhibition is a systemic decrease in sex hormone production.
4. Ultimately, this leads to reliable inhibition of the proliferation of all hormone-dependent tissues in the body.

Pharmacokinetics and administration rules

The drug is intended exclusively for oral administration. After absorption in the gastrointestinal tract, it is rapidly distributed throughout tissues, reaching its central targets.

The most important pharmacokinetic parameter is the half-life ($t_{1/2}$), which for this 17α-ethynyltestosterone derivative is only 1.5 hours. Such a short half-life dictates the need for strict adherence to the dosing regimen to avoid sharp fluctuations in the concentration of the substance in blood plasma and to ensure continuous suppression of the hypothalamo-pituitary axis.

Indications for clinical practice

The drug's ability to cause medicinal atrophy of hormone-dependent structures determines the range of its clinical applications. In modern medical practice, the following main indications are distinguished:

• Endometriosis and infertility developing against its background. Suppression of FSH and LH secretion deprives endometriotic foci of the stimulating influence of hormones, which halts their growth.
• Benign breast diseases. The drug demonstrates high efficacy in the treatment of mastopathy, macromastia (abnormal enlargement of the mammary glands), and gynecomastia.
• Primary menorrhagia. Prescribed for the correction of heavy uterine bleeding.
• Hereditary angioedema. Used as a prophylactic agent to prevent exacerbations of this condition.

Side effects and strict contraindications

Interference with delicate neuroendocrine regulation is inevitably associated with the risk of adverse reactions. Side effects affect various systems:

• Central nervous system: patients often report headache, episodes of dizziness, and nervousness.
• Gastrointestinal tract: therapy may be complicated by dyspepsia and impaired liver function.
• Vascular system: the appearance of vasomotor reactions in the form of "hot flashes" is characteristic, which is directly related to the artificially induced decrease in sex hormone levels.

Prescribing the drug requires a thorough medical history, as there are strict contraindications. These include pregnancy, lactation, and the presence of porphyria in the patient.

Briefly: answers to topical questions

Class and exam questions

What else to study on this topic

• Danazol's affinity for androgen and glucocorticoid receptors: clinical significance
• Mechanisms of dyspepsia and hepatotoxicity development during steroid drug administration
• Pathogenesis of porphyria and reasons for contraindicating steroids in this condition
• The role of gonadotropin-releasing hormone in the regulation of the menstrual cycle
• Principles of preventing exacerbations of hereditary angioedema

Other topics in the section "Hormone preparations, their synthetic substitutes, and antagonists"

Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.